James D Dunbar
Overview
Explore the profile of James D Dunbar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
1231
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sloop K, Cox A, Wainscott D, White A, Droz B, Stutsman C, et al.
Sci Transl Med
. 2024 Dec;
16(778):eadp5765.
PMID: 39693407
Orally bioavailable, synthetic nonpeptide agonists (NPAs) of the glucagon-like peptide-1 receptor (GLP-1R) may offer an effective, scalable pharmacotherapy to address the metabolic disease epidemic. One of the first molecules in...
2.
Benichou O, Coskun T, Gonciarz M, Garhyan P, Adams A, Du Y, et al.
Cell Metab
. 2023 Jan;
35(2):274-286.e10.
PMID: 36630958
GDF15 and its receptor GFRAL/RET form a non-homeostatic system that regulates food intake and body weight in preclinical species. Here, we describe a GDF15 analog, LY3463251, a potent agonist at...
3.
Sun B, Willard F, Feng D, Alsina-Fernandez J, Chen Q, Vieth M, et al.
Proc Natl Acad Sci U S A
. 2022 Mar;
119(13):e2116506119.
PMID: 35333651
SignificanceTirzepatide is a dual agonist of the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R), which are incretin receptors that regulate carbohydrate metabolism. This investigational agent has...
4.
Worth A, Shoop R, Tye K, Feetham C, DAgostino G, Dodd G, et al.
Elife
. 2020 Jul;
9.
PMID: 32723474
The cytokine, GDF15, is produced in pathological states which cause cellular stress, including cancer. When over expressed, it causes dramatic weight reduction, suggesting a role in disease-related anorexia. Here, we...
5.
Lewis J, Samms R, Cooper S, Luckett J, Perkins A, Dunbar J, et al.
Endocrinology
. 2017 Sep;
158(10):3090-3096.
PMID: 28938451
The increased prevalence of obesity and its cardiometabolic implications demonstrates the imperative to identify novel therapeutic targets able to effect meaningful metabolic changes in this population. Antibody-mediated targeting of fibroblast...
6.
Kharitonenkov A, Beals J, Micanovic R, Strifler B, Rathnachalam R, Wroblewski V, et al.
PLoS One
. 2013 Mar;
8(3):e58575.
PMID: 23536797
Fibroblast growth factor 21 is a novel hormonal regulator with the potential to treat a broad variety of metabolic abnormalities, such as type 2 diabetes, obesity, hepatic steatosis, and cardiovascular...
7.
Adams A, Coskun T, Irizarry Rovira A, Schneider M, Raches D, Micanovic R, et al.
PLoS One
. 2012 Jun;
7(5):e38438.
PMID: 22675463
Fibroblast growth factors 19 (FGF19) and 21 (FGF21) have emerged as key regulators of energy metabolism. Several studies have been conducted to understand the mechanism of FGF19 and FGF21 action,...
8.
Zhao Y, Dunbar J, Kharitonenkov A
Adv Exp Med Biol
. 2012 Mar;
728:214-28.
PMID: 22396172
The prevalence of obesity and diabetes has been dramatically increasing during the last decade suggesting a greater patient need for more efficacious and safer drugs. Large molecule therapy has played...
9.
Pincheira R, Baerwald M, Dunbar J, Donner D
EMBO J
. 2009 Jan;
28(3):261-73.
PMID: 19131967
By screening a fetal brain two-hybrid library with the death domain of the p75 neurotrophin receptor (NTR), we identified the Sall2 transcription factor as a novel interacting protein. Sall2 is...
10.
Micanovic R, Raches D, Dunbar J, Driver D, Bina H, Dickinson C, et al.
J Cell Physiol
. 2009 Jan;
219(2):227-34.
PMID: 19117008
Fibroblast growth factor 21 is a member of endocrine FGFs subfamily, along with FGF19 and FGF23. It is emerging as a novel regulator with beneficial effects on a variety of...